| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 5. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | bismuth/metronidazole/tetracycline (Pylera®) |
| Formulation | 140 mg/125 mg/125 mg capsule |
| Reference number | 1544 |
| Indication | For use in combination with omeprazole for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active, or a history of, H. pylori associated ulcers. |
| Company | Flynn Pharma |
| BNF chapter | Gastro-intestinal system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 06/12/2023 |
| Further information AWMSG position statement on the appraisal of antimicrobial medicines |
|